Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antitubercular Agents"" wg kryterium: Temat


Tytuł :
Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.
Autorzy :
Li P; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China.
Wang B; Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing, 101149, PR China.
Fu L; Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing, 101149, PR China.
Guo K; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China.
Ma C; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China.
Wang B; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China.
Lin Z; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China.
Li G; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China. Electronic address: .
Huang H; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China; Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China. Electronic address: .
Lu Y; Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing, 101149, PR China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113603. Date of Electronic Publication: 2021 Jun 05.
Typ publikacji :
Journal Article
MeSH Terms :
Amides/*pharmacology
Antitubercular Agents/*pharmacology
Benzopyrans/*pharmacology
Esters/*pharmacology
Mycobacterium tuberculosis/*drug effects
Amides/chemistry ; Amides/metabolism ; Antitubercular Agents/chemistry ; Antitubercular Agents/metabolism ; Benzopyrans/chemistry ; Benzopyrans/metabolism ; Dose-Response Relationship, Drug ; Esters/chemistry ; Esters/metabolism ; Microbial Sensitivity Tests ; Molecular Structure ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
The Mur Enzymes Chink in the Armour of Mycobacterium tuberculosis cell wall.
Autorzy :
Shinde Y; Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, District Dhule, 425405, Maharashtra, India.
Ahmad I; Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, District Dhule, 425405, Maharashtra, India.
Surana S; Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, District Dhule, 425405, Maharashtra, India.
Patel H; Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, District Dhule, 425405, Maharashtra, India. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113568. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antitubercular Agents/*pharmacology
Enzyme Inhibitors/*pharmacology
Mycobacterium tuberculosis/*enzymology
Peptide Synthases/*antagonists & inhibitors
Peptidoglycan/*pharmacology
Antitubercular Agents/chemical synthesis ; Antitubercular Agents/chemistry ; Cell Wall/drug effects ; Cell Wall/metabolism ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Molecular Structure ; Mycobacterium tuberculosis/cytology ; Peptide Synthases/metabolism ; Peptidoglycan/chemistry
Czasopismo naukowe
Tytuł :
A hydrogel-based implantable multidrug antitubercular formulation outperforms oral delivery.
Autorzy :
Pal S; Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad-121001, Haryana, India. .
Soni V
Kumar S
Jha SK
Medatwal N
Rana K
Yadav P
Mehta D
Jain D
Sharma P
Kar R
Srivastava A
Patil VS
Dasgupta U
Nandicoori VK
Bajaj A
Pokaż więcej
Źródło :
Nanoscale [Nanoscale] 2021 Aug 21; Vol. 13 (31), pp. 13225-13230. Date of Electronic Publication: 2021 Jul 30.
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents*/pharmacology
Antitubercular Agents*/therapeutic use
Hydrogels*
Animals ; Ethambutol ; Isoniazid ; Mice ; Pyrazinamide
Czasopismo naukowe
Tytuł :
Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis.
Autorzy :
Melo de Oliveira VN; Department of Fundamental Chemistry, Federal University of Pernambuco, 50.740-540, Recife, Brazil.
Flávia do Amaral Moura C; Department of Chemistry, Federal Rural University of Pernambuco, Dois Irmãos, 52171-900, Recife, Brazil.
Peixoto ADS; Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Brazil.
Gonçalves Ferreira VP; Laboratorio de Oncologia Experimental, Nucleo de Pesquisa Em Desenvolvimento de Medicamentos (NPDM), Universidade Federal Do Ceara, Fortaleza, Brazil; Oswaldo Cruz Foundation (Fiocruz), Eusebio, Brazil.
Araújo HM; Laboratorio de Oncologia Experimental, Nucleo de Pesquisa Em Desenvolvimento de Medicamentos (NPDM), Universidade Federal Do Ceara, Fortaleza, Brazil; Oswaldo Cruz Foundation (Fiocruz), Eusebio, Brazil.
Lapa Montenegro Pimentel LM; Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Brazil.
Pessoa CDÓ; Laboratorio de Oncologia Experimental, Nucleo de Pesquisa Em Desenvolvimento de Medicamentos (NPDM), Universidade Federal Do Ceara, Fortaleza, Brazil.
Nicolete R; Laboratorio de Oncologia Experimental, Nucleo de Pesquisa Em Desenvolvimento de Medicamentos (NPDM), Universidade Federal Do Ceara, Fortaleza, Brazil; Oswaldo Cruz Foundation (Fiocruz), Eusebio, Brazil.
Versiani Dos Anjos J; Department of Fundamental Chemistry, Federal University of Pernambuco, 50.740-540, Recife, Brazil.
Sharma PP; Laboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College University Enclave, University of Delhi, Delhi, India.
Rathi B; Laboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College University Enclave, University of Delhi, Delhi, India.
Pena LJ; Department of Virology, Oswaldo Cruz Foundation, Fiocruz, 50740-465, Recife, PE, Brazil.
Rollin P; Universite D'Orleans et CNRS, ICOA, UMR 7311, BP 6759, F-45067, Orleans, France.
Tatibouët A; Universite D'Orleans et CNRS, ICOA, UMR 7311, BP 6759, F-45067, Orleans, France.
Nascimento de Oliveira R; Department of Chemistry, Federal Rural University of Pernambuco, Dois Irmãos, 52171-900, Recife, Brazil. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Aug 05; Vol. 220, pp. 113472. Date of Electronic Publication: 2021 Apr 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Antitubercular Agents/*pharmacology
Carcinoma, Squamous Cell/*drug therapy
Glycoconjugates/*pharmacology
Lung Neoplasms/*drug therapy
Mycobacterium tuberculosis/*drug effects
Oxadiazoles/*chemistry
Alkynes/chemistry ; Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Antitubercular Agents/chemical synthesis ; Antitubercular Agents/chemistry ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/pathology ; Cell Line ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Chlorocebus aethiops ; Dose-Response Relationship, Drug ; Drug Discovery ; Glycoconjugates/chemical synthesis ; Glycoconjugates/chemistry ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Mice ; Microbial Sensitivity Tests ; Molecular Structure ; Structure-Activity Relationship ; Triazoles/chemistry
Czasopismo naukowe
Tytuł :
Antitubercular metabolites from the marine-derived fungus strain Aspergillus fumigatus MF029.
Autorzy :
Song Z; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Liu Y; China Astronaut Research and Training Center, Beijing, China.
Gao J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; School of Food and biological Engineering, Hefei University of Technology, Hefei, China.
Hu J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
He H; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Dai S; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Wang L; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Dai H; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Zhang L; State Key Laboratory of Bioreactor Engineering, East China University of Science of Technology, Shanghai, China.
Song F; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Pokaż więcej
Źródło :
Natural product research [Nat Prod Res] 2021 Aug; Vol. 35 (16), pp. 2647-2654. Date of Electronic Publication: 2019 Sep 06.
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents*/isolation & purification
Antitubercular Agents*/pharmacology
Aspergillus fumigatus*/chemistry
Biological Products/*pharmacology
Aquatic Organisms ; Biological Products/isolation & purification ; Microbial Sensitivity Tests
Czasopismo naukowe
Tytuł :
High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda.
Autorzy :
Martin MK; Department of Population Studies, School of Statistics and Planning, School of Statistics and Planning, College of Business and Management Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda. .; University Research Co., LLC, Kampala, Uganda. .
Paul OJ; University Research Co., LLC, Kampala, Uganda.
Sara R; University Research Co., LLC, Washington, DC, USA.
Hilary A; University Research Co., LLC, Kampala, Uganda.
Frank M; National TB and Leprosy Control Division, Ministry of Health, Kampala, Uganda.
Augustin MK; University Research Co., LLC, Kampala, Uganda.
Stavia T; National TB and Leprosy Control Division, Ministry of Health, Kampala, Uganda.
Christopher W; University Research Co., LLC, Kampala, Uganda.
van Zanten TV; University Research Co., LLC, Washington, DC, USA.
Gladys T; University Research Co., LLC, Kampala, Uganda.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2021 Oct 12; Vol. 21 (1), pp. 1060. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents*/therapeutic use
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Adult ; Cross-Sectional Studies ; Female ; Follow-Up Studies ; Hospitals ; Humans ; Referral and Consultation ; Retrospective Studies ; Uganda/epidemiology
Czasopismo naukowe
Tytuł :
A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries.
Autorzy :
Fekadu G; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
Yao J; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
You JHS; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
Pokaż więcej
Źródło :
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2021 Oct; Vol. 21 (5), pp. 897-910. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antitubercular Agents/*administration & dosage
Diarylquinolines/*administration & dosage
Tuberculosis, Multidrug-Resistant/*drug therapy
Administration, Oral ; Antitubercular Agents/economics ; Cost-Benefit Analysis ; Diarylquinolines/economics ; Economics, Pharmaceutical ; Humans ; Markov Chains ; Tuberculosis, Multidrug-Resistant/economics ; Tuberculosis, Multidrug-Resistant/microbiology
Czasopismo naukowe
Tytuł :
Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis.
Autorzy :
Fu L; Pulmonary Diseases Department Two, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China.
Weng T; Departments of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Sun F; Departments of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Zhang P; Pulmonary Diseases Department Two, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China.
Li H; Pulmonary Diseases Department Two, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China.
Li Y; Departments of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yang Q; Guangdong Key Lab for Diagnosis &Treatment of Emerging Infectious Disease, Shenzhen Third People's Hospital, National clinical research center for infectious disease, Southern University of Science and Technology, Shenzhen, 518112, China.
Cai Y; Department of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, Shenzhen, 518060, China.
Zhang X; The Fourth People's Hospital of Foshan, Foshan, 528000, China.
Liang H; Tuberculosis Diseases Department Two, The Sixth People's Hospital of Dongguan, Dongguan, 523000, China.
Chen X; Department of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, Shenzhen, 518060, China.
Wang Z; Pulmonary Diseases Department Two, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China.
Liu L; Pulmonary Diseases Department Two, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China. Electronic address: .
Zhang W; Departments of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China. Electronic address: .
Deng G; Pulmonary Diseases Department Two, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China. Electronic address: .
Pokaż więcej
Źródło :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Oct; Vol. 111, pp. 138-147. Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :
Controlled Clinical Trial; Journal Article
MeSH Terms :
Antitubercular Agents*/adverse effects
Tuberculosis, Multidrug-Resistant*/drug therapy
Diarylquinolines/adverse effects ; Humans ; Prospective Studies
Czasopismo naukowe
Tytuł :
Traditional Medicinal Plants as a Source of Antituberculosis Drugs: A System Review.
Autorzy :
Xu Y; Institute of Chinese Materia Medica, China Academy of Chinese Medical Science, Beijing 100700, China.
Liang B; Department of Traditional Chinese Medicine, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Kong C; Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.; Beijing Key Laboratory in Drug Resistant Tuberculosis Research, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China.
Sun Z; Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.; Beijing Key Laboratory in Drug Resistant Tuberculosis Research, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China.
Pokaż więcej
Źródło :
BioMed research international [Biomed Res Int] 2021 Sep 08; Vol. 2021, pp. 9910365. Date of Electronic Publication: 2021 Sep 08 (Print Publication: 2021).
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antitubercular Agents/*pharmacology
Medicine, Traditional/*methods
Plants, Medicinal/*classification
Antitubercular Agents/metabolism ; Humans ; Microbial Sensitivity Tests ; Mycobacterium tuberculosis ; Phytotherapy/methods ; Plant Extracts/pharmacology
Czasopismo naukowe
Tytuł :
Empirical anti-tuberculous therapy for the massive pericardial effusion of unknown etiology.
Autorzy :
Wang C; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Fang L; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Zhu W; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Lin X; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Guo X; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Chen A; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Zhang L; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Liu Y; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Lai J; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Wu W; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Li L; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Yang J; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Yan X; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Zhang S; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło :
Current medical research and opinion [Curr Med Res Opin] 2021 Sep; Vol. 37 (9), pp. 1507-1513. Date of Electronic Publication: 2021 Jul 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antitubercular Agents*/therapeutic use
Pericardial Effusion*/drug therapy
Pericardial Effusion*/etiology
Tuberculosis*/complications
Tuberculosis*/drug therapy
China ; Humans ; Incidence ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.
Autorzy :
Li J; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Yang G; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Cai Q; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Wang Y; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Xu Y; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Zhang R; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: .
Lang Y; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: .
Cai X; Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: .
Pokaż więcej
Źródło :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Sep; Vol. 110, pp. 179-186. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents*/adverse effects
Tuberculosis, Multidrug-Resistant*/drug therapy
China ; Diarylquinolines/adverse effects ; Humans
Czasopismo naukowe
Tytuł :
How a new drug is born.
Autorzy :
Caporali A; University/BHF Centre for Cardiovascular Science, the University of Edinburgh, 47 Little France Crescent, Edinburgh, Scotland, EH16 4TJ, UK.
Fawell S; Early Oncology, AstraZeneca, 35 Gatehouse Park, Waltham, MA 02451, USA.
Scaltriti M; Early Oncology, AstraZeneca, 35 Gatehouse Park, Waltham, MA 02451, USA.
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2021 Aug 21; Vol. 42 (32), pp. 3039-3041.
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents*/therapeutic use
Pharmaceutical Preparations*
Humans
Czasopismo naukowe
Tytuł :
Trends in primary multidrug-resistant tuberculosis in the State of Rio de Janeiro: a retrospective study conducted during 2000-2019.
Autorzy :
Bhering M; Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.; Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública Sergio Arouca, Rio de Janeiro, RJ, Brasil.
Kritski A; Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Programa Acadêmico de Tuberculose, Rio de Janeiro, RJ, Brasil.
Pokaż więcej
Źródło :
Revista da Sociedade Brasileira de Medicina Tropical [Rev Soc Bras Med Trop] 2021 Aug 20; Vol. 54, pp. e00862021. Date of Electronic Publication: 2021 Aug 20 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents*/therapeutic use
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Brazil/epidemiology ; Humans ; Research Design ; Retrospective Studies
Czasopismo naukowe
Tytuł :
A turn-on probe for detecting antituberculotic drug-induced liver injury in mice via NIR-II fluorescence/optoacoustic imaging.
Autorzy :
Chen L; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, College of Materials Science and Engineering, South China University of Technology, Guangzhou 510640, China. .
Chen J; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, College of Materials Science and Engineering, South China University of Technology, Guangzhou 510640, China. .
Fang Y; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, College of Materials Science and Engineering, South China University of Technology, Guangzhou 510640, China. .
Zeng F; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, College of Materials Science and Engineering, South China University of Technology, Guangzhou 510640, China. .
Wu S; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, College of Materials Science and Engineering, South China University of Technology, Guangzhou 510640, China. .
Pokaż więcej
Źródło :
Chemical communications (Cambridge, England) [Chem Commun (Camb)] 2021 Aug 05; Vol. 57 (63), pp. 7842-7845.
Typ publikacji :
Journal Article
MeSH Terms :
Optical Imaging*
Photoacoustic Techniques*
Antitubercular Agents/*analysis
Chemical and Drug Induced Liver Injury/*diagnostic imaging
Fluorescent Dyes/*chemistry
Animals ; Antitubercular Agents/adverse effects ; Infrared Rays ; Mice ; Molecular Structure ; RAW 264.7 Cells
Czasopismo naukowe
Tytuł :
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Autorzy :
Aldridge BB; Tufts University, Boston, MA, USA.
Barros-Aguirre D; GlaxoSmithKline, Tres Cantos, Spain.
Barry CE 3rd; National Institutes of Health, Bethesda, MD, USA.
Bates RH; GlaxoSmithKline, Tres Cantos, Spain.
Berthel SJ; Panorama Global, Seattle, WA, USA.
Boshoff HI; National Institutes of Health, Bethesda, MD, USA.
Chibale K; University of Cape Town, Cape Town, South Africa.
Chu XJ; Global Health Drug Discovery Institute, Beijing, China.
Cooper CB; Global Alliance for TB Drug Development, New York, NY, USA.
Dartois V; Hackensack Meridian Health Center for Discovery & Innovation, Nutley, NJ, USA.
Duncan K; Bill & Melinda Gates Foundation, Seattle, WA, USA.
Fotouhi N; Global Alliance for TB Drug Development, New York, NY, USA.
Gusovsky F; Eisai, Andover, MA, USA.
Hipskind PA; Lgenia, Fortville, IN, USA.
Kempf DJ; AbbVie, North Chicago, IL, USA.
Lelièvre J; GlaxoSmithKline, Tres Cantos, Spain.
Lenaerts AJ; Colorado State University, Fort Collins, CO, USA.
McNamara CW; Calibr, a division of the Scripps Research Institute, La Jolla, CA, USA.
Mizrahi V; University of Cape Town, Cape Town, South Africa.
Nathan C; Weill Cornell Medicine, New York, NY, USA. .
Olsen DB; Merck & Co., West Point, PA, USA.
Parish T; Seattle Children's Research Institute, Seattle, WA, USA.
Petrassi HM; Calibr, a division of the Scripps Research Institute, La Jolla, CA, USA.
Pym A; Janssen-Cilag, Buckinghamshire, UK.
Rhee KY; Weill Cornell Medicine, New York, NY, USA.
Robertson GT; Colorado State University, Fort Collins, CO, USA.
Rock JM; The Rockefeller University, New York, NY, USA.
Rubin EJ; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Russell B; Bill & Melinda Gates Medical Research Institute, Boston, MA, USA.
Russell DG; Cornell University, Ithaca, NY, USA.
Sacchettini JC; Texas A&M University, College Station, TX, USA.
Schnappinger D; Weill Cornell Medicine, New York, NY, USA.
Schrimpf M; AbbVie, North Chicago, IL, USA.
Upton AM; Evotec, Lyon, France.
Warner P; Bill & Melinda Gates Foundation, Seattle, WA, USA.
Wyatt PG; Drug Discovery Unit, University of Dundee, Dundee, Scotland.
Yuan Y; Global Health Drug Discovery Institute, Beijing, China.
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2021 Aug; Vol. 27 (8), pp. 1333-1337.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Antitubercular Agents/*therapeutic use
Tuberculosis/*drug therapy
Antitubercular Agents/chemistry ; Humans ; Learning ; Time Factors
Czasopismo naukowe
Tytuł :
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Autorzy :
Wallis RS; The Aurum Institute, Johannesburg, South Africa; Department of Medicine, Vanderbilt University, Nashville, TN, USA; Department of Medicine, Case Western Reserve University, Cleveland, OH, USA. Electronic address: .
Ginindza S; The Aurum Institute, Johannesburg, South Africa.
Beattie T; The Aurum Institute, Johannesburg, South Africa.
Arjun N; The Aurum Institute, Johannesburg, South Africa.
Likoti M; The Aurum Institute, Johannesburg, South Africa.
Edward VA; The Aurum Institute, Johannesburg, South Africa; Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Rassool M; Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa; Clinical HIV Research Unit, Johannesburg, South Africa.
Ahmed K; Setshaba Research Centre, Soshanguve, South Africa; Department of Medical Microbiology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa.
Fielding K; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Ahidjo BA; The Aurum Institute, Johannesburg, South Africa.
Vangu MDT; Nuclear Medicine and Molecular Imaging, CM Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.
Churchyard G; The Aurum Institute, Johannesburg, South Africa; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Pokaż więcej
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Aug; Vol. 9 (8), pp. 897-908. Date of Electronic Publication: 2021 Mar 16.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antitubercular Agents/*administration & dosage
Auranofin/*administration & dosage
Ergocalciferols/*administration & dosage
Everolimus/*administration & dosage
Phosphodiesterase 4 Inhibitors/*administration & dosage
Tuberculosis, Pulmonary/*drug therapy
Adult ; Antitubercular Agents/adverse effects ; Auranofin/adverse effects ; Auranofin/pharmacology ; Double-Blind Method ; Drug Therapy, Combination ; Ergocalciferols/adverse effects ; Ergocalciferols/pharmacology ; Everolimus/adverse effects ; Everolimus/pharmacology ; Female ; Forced Expiratory Volume/drug effects ; Humans ; Male ; Middle Aged ; Mycobacterium tuberculosis ; Phosphodiesterase 4 Inhibitors/adverse effects ; Phosphodiesterase 4 Inhibitors/pharmacology ; Prospective Studies ; South Africa ; Sputum/drug effects ; Sputum/microbiology
Czasopismo naukowe
Tytuł :
Early and Midterm Outcomes of Endovascular Repair of Tuberculous Infected Native (Mycotic) Aortic Aneurysms.
Autorzy :
He H; Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Li Q; Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Wang J; Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Li X; Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Li J; Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Shu C; Department of Vascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China; Department of Vascular Surgery, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery [Eur J Vasc Endovasc Surg] 2021 Aug; Vol. 62 (2), pp. 314-315. Date of Electronic Publication: 2021 Jun 06.
Typ publikacji :
Letter
MeSH Terms :
Endovascular Procedures*/methods
Antitubercular Agents/*administration & dosage
Aortic Aneurysm/*etiology
Aortic Aneurysm/*surgery
Tuberculosis/*complications
Aged ; Antitubercular Agents/therapeutic use ; Blood Vessel Prosthesis ; Drug-Eluting Stents ; Female ; Humans ; Isoniazid/administration & dosage ; Male ; Middle Aged ; Postoperative Complications/etiology ; Retrospective Studies ; Rifampin/administration & dosage ; Survival Rate ; Treatment Outcome ; Tuberculosis/drug therapy
Opinia redakcyjna
Tytuł :
In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis .
Autorzy :
Deb PK; Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, Jordan.
Al-Shar'i NA; Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Venugopala KN; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia.; Department of Biotechnology and Food Technology, Durban University of Technology, Durban, South Africa.
Pillay M; Department of Microbiology, National Health Laboratory Services, KZN Academic Complex, Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Borah P; Pratiksha Institute of Pharmaceutical Sciences, Guwahati, India.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 869-884.
Typ publikacji :
Journal Article
MeSH Terms :
Antitubercular Agents/*pharmacology
Mycobacterium tuberculosis/*drug effects
Oxadiazoles/*pharmacology
Antitubercular Agents/chemical synthesis ; Antitubercular Agents/chemistry ; Dose-Response Relationship, Drug ; Microbial Sensitivity Tests ; Models, Molecular ; Molecular Structure ; Oxadiazoles/chemical synthesis ; Oxadiazoles/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Benzoheterocyclic Oxime Carbamates Active against Mycobacterium tuberculosis : Synthesis, Structure-Activity Relationship, Metabolism, and Biology Triaging.
Autorzy :
van der Westhuyzen R; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Mabhula A; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Njaria PM; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Müller R; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Ngumbu Muhunga D; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Taylor D; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Lawrence N; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Njoroge M; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Brunschwig C; Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Moosa A; SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Singh V; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Rao SPS; Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore.
Manjunatha UH; Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore.
Smith PW; Novartis Institute for Tropical Diseases (NITD), 10 Biopolis Road, Chromos #05-01, Singapore 138670, Singapore.
Warner DF; SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Street LJ; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Chibale K; Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Jul 08; Vol. 64 (13), pp. 9444-9457. Date of Electronic Publication: 2021 Jun 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antitubercular Agents/*pharmacology
Carbamates/*pharmacology
Heterocyclic Compounds/*pharmacology
Mycobacterium tuberculosis/*drug effects
Oximes/*pharmacology
Antitubercular Agents/chemistry ; Antitubercular Agents/metabolism ; Carbamates/chemistry ; Carbamates/metabolism ; Dose-Response Relationship, Drug ; Heterocyclic Compounds/chemistry ; Heterocyclic Compounds/metabolism ; Microbial Sensitivity Tests ; Molecular Structure ; Mycobacterium tuberculosis/metabolism ; Oximes/chemistry ; Oximes/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Semisynthetic modifications of antitubercular lanostane triterpenoids from Ganoderma.
Autorzy :
Chinthanom P; National Center for Genetic Engineering and Biotechnology (BIOTEC), Klong Luang, Pathumthani, Thailand.
Vichai V; National Center for Genetic Engineering and Biotechnology (BIOTEC), Klong Luang, Pathumthani, Thailand.
Dokladda K; National Center for Genetic Engineering and Biotechnology (BIOTEC), Klong Luang, Pathumthani, Thailand.
Sappan M; National Center for Genetic Engineering and Biotechnology (BIOTEC), Klong Luang, Pathumthani, Thailand.
Thongpanchang C; National Center for Genetic Engineering and Biotechnology (BIOTEC), Klong Luang, Pathumthani, Thailand.
Isaka M; National Center for Genetic Engineering and Biotechnology (BIOTEC), Klong Luang, Pathumthani, Thailand. .
Pokaż więcej
Źródło :
The Journal of antibiotics [J Antibiot (Tokyo)] 2021 Jul; Vol. 74 (7), pp. 435-442. Date of Electronic Publication: 2021 May 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antitubercular Agents/*chemistry
Antitubercular Agents/*pharmacology
Ganoderma/*chemistry
Triterpenes/*chemistry
Animals ; Antitubercular Agents/toxicity ; Chlorocebus aethiops ; Ganoderma/growth & development ; Microbial Sensitivity Tests ; Molecular Structure ; Mycobacterium tuberculosis/drug effects ; Structure-Activity Relationship ; Triterpenes/chemical synthesis ; Triterpenes/pharmacology ; Vero Cells
SCR Organism :
Ganoderma australe
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies